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Abstract
Tumors affect myelopoeisis and induce the expansion of myeloid cells with immunosuppressive activity. In the MT/ret
model of spontaneous metastatic melanoma, myeloid cells are the most abundant tumor infiltrating hematopoietic
population and their proportion is highest in the most aggressive cutaneous metastasis. Our data suggest that the tumor
microenvironment favors polarization of myeloid cells into type 2 cells characterized by F4/80 expression, a weak capacity to
secrete IL-12 and a high production of arginase. Myeloid cells from tumor and spleen of MT/ret mice inhibit T cell
proliferation and IFNc secretion. Interestingly, T cells play a role in type 2 polarization of myeloid cells. Indeed, intra-tumoral
myeloid cells from MT/ret mice lacking T cells are not only less suppressive towards T cells than corresponding cells from
wild-type MT/ret mice, but they also inhibit more efficiently melanoma cell proliferation. Thus, our data support the
existence of a vicious circle, in which T cells may favor cancer development by establishing an environment that is likely to
skew myeloid cell immunity toward a tumor promoting response that, in turn, suppresses immune effector cell functions.
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Introduction
Tumor development affects bone marrow myelopoeisis and
induces the expansion of myeloid derived suppressive cells
(MDSC) [1]. In mouse models, MDSC express the aM integrin
CD11b and the myeloid lineage differentiation antigen Ly6C/G
recognized by the Gr1 antibody. CD11b
+Gr1
+ cells represent 2–
4% of splenocytes of normal mice, but increase 5- to 20- fold in
mice transplanted with tumors [2]. Tumor-induced CD11b
+Gr1
+
splenocytes are considered to be a heterogeneous population of
immature monocytes/macrophages, granulocytes, dendritic cells
and their progenitors [3,4,5]. It is established that MDSC suppress
conventional T cell proliferation and activation [6]. In addition,
MDSC have been suggested to impact the functions of other cells
including NK, macrophages and regulatory T cells [7,8,9].
Dissection of their properties is hampered by the lack of specific
marker. The a chain of the IL4 receptor (IL-4Ra) [10] and the
M-CSF receptor (CD115) [11] have been proposed to help
identifying subpopulations of mouse MDSC. Nevertheless, they do
not identify immune suppressive populations of MDSC in various
tumor models [12].
Macrophages have long been recognized as important compo-
nents of the innate immunity against tumors [13]. While tumor
associated macrophages (TAM) can prevent the establishment and
spread of tumor cells, they may also favor tumor growth and
dissemination. This paradox is due to the inherent plasticity of
macrophages, which can display distinct phenotypes and functions
in response to different signals [14,15,16]. M1 macrophages
secrete IL-12 and NO, promote antitumor immunity and directly
kill tumor cells, whereas alternatively activated M2 macrophages
exhibit defective production of IL-12, high IL-10 secretion,
produce arginase, suppress the antitumor response and promote
angiogenesis and metastasis [17,18,19,20]. Accordingly, TAM
favor tumor progression in most mouse models [21,22,23,24], but
are vital for tumor eradication in others [25,26], suggesting that
TAM display contradictory roles depending on the tumor type
which might dictate their polarization [27].
Only few recent data have shown that immune cells within the
tumor microenvironment may influence the pro-tumoral prop-
erties of tumor infiltrating macrophages. De Visser et al were the
first to demonstrate the requirement of B cells in mediating
the recruitment of inflammatory cells into premalignant skin
associated with neoplastic progression using the model of HPV16
induced epithelial carcinogenesis [28]. More recently, B cells
have been shown to play a role in driving M2 like polarization of
TAM [29]. Sinha et al have shown that MDSC suppress tumor
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dependent mechanism [9]. In addition, although some subsets of
lymphocytes including cytotoxic CD8
+ T cells and NK cells
exhibit anti-tumor immunity [30], other subsets notably Th2
cells, CD4
+ regulatory T cells and NKT cells may exhibit
opposite effect on tumor progression by interfering with TAM
properties [31]. Thus, various immune cells seem to contribute to
myeloid orientation although the relative contribution of the
different cell types during spontaneous development of tumors is
unclear.
In the model of spontaneous melanoma driven by the RET
oncogene (MT/ret mice; [32]), the primary uveal tumor cells
disseminate at three weeks of age, but remain dormant for several
weeks [33]. 50% of 3 month old mice display cutaneous metastasis
and finally develop visceral metastasis [34]. In this MT/ret model,
we have shown that CD8
+ T cell depletion does not accelerate the
onset of cutaneous metastasis, suggesting the presence of tumor
induced immunosuppressive factors locally. In the present study,
we focused our interest on the characterization of myeloid cells
within cutaneous metastasis. Given the critical role of adaptative
immunity in regulating innate immune cell functions in some
mouse models of cancer development [14], we addressed the
possibility that T cells might exert a role in regulating recruitment
and/or pro-tumor properties of tumor infiltrating myeloid cells in
MT/ret mice. We report that myeloid cells are the most abundant
hematopoietic population within the cutaneous metastasis and that
they display immune suppressive functions. Our data further
established the critical role of T cells in the acquisition of pro-
tumoral properties of intra-tumoral myeloid cells in the course of
melanoma development.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice in compliance with French Ministry of Agriculture regu-
lations for animal experimentation. The animal experiment pro-
tocol approval number is 75–510 and was delivered by the
veterinary departement of Paris. All experiments were performed
in animal facilities which also received an approval number
(A75-14-02).
Mice
MT/ret transgenic mice express the human Ret oncogene [32].
3 to six month old mice at different stages of malignancy were used
and age-matched non-transgenic MT/ret
2/2 littermates were
used as control (ctrl). MT/ret mice were crossed with C57BL/6
CD3e
2/2 mice [35] to obtain RetCD3eKO and RetCD3e
+/2
(called RetCD3e
+ later) mice. MT/ret, RetCD3eKO and
RetCD3e
+ mice were diagnosed for recording the development
of exophthalmus related to the uveal primary melanoma, and
subsequent cutaneous metastasis. All mice are maintained in our
own pathogen free animal facilities. OT-1 mice expressing a TCR
specific for Ova257-264 were purchased from Charles River
Laboratories.
Cell suspension procedures from lymphoid organs and
tumors
Spleens and cutaneous tumor masses were mechanically
dissociated and digested with 1mg/mL collagenase A and
0,1mg/mL DNase I (Roche, Mannheim, Germany) for 25 min
at 37uC. Single cell suspensions were filtered, washed in PBS 1X,
5% FCS, 0.5 mM EDTA and resuspended in RPMI 1640.
Flow cytometry
After blocking with anti-FccR Ab, cell suspensions were stained
with the following mAbs against CD45.2, CD11b, Gr1, TcRab,
TcRcd, CD8a, CD4, CD19 and CD124 from Pharmingen (BD
Biosciences, Le Pont de Claix, France), NK1.1 from eBiosciences
(San Diego, CA) and F4/80 from Serotec (Du ¨sseldorf, Germany).
For IL-12 intracytoplasmic staining, cell suspensions were sti-
mulated overnight with 2 mM Golgi Stop Monensin, 0.1 mg/ml
LPS and 101ng/ml IFNc. The staining was performed following
the manufacturer’s instructions (kit Cytofix/cytoperm, BD Bio-
sciences) using the combination CD45.2, CD11b, and IL-12.
Analyses were performed on a FacsCalibur cytofluorometer (BD
Biosciences).
Isolation of myeloid cells and supernatants
CD11b
+ cells from spleens and cutaneous nodules were selected
via magnetic microbeads conjugated to anti-mouse CD11b mAb
(Mac-1; Miltenyi Biotec) using MS columns according to the
manufacturer’s specifications (Miltenyi Biotec). For supernatant
collection, 5.10
5 cells per ml were cultured for 48 h in complete
medium at 37uC.
IFNc-ELISpot
Ctrl mice were immunized with 50 mg of peptide 33–41 from
LCMV glycoprotein (GP33:KAVYNFATM) in IFA. Eight days
later, inguinal lymph node cells were collected. ELISpot was
performed using the mouse IFNc ELISpot kit (BD Biosciences).
GP33-specific T cells (2.10
5 cells/well) were stimulated 24 h with
GP33 (10-7M) in the presence of CD11b
+ or CD11b
- cells (10
4
cells/well) or corresponding myeloid derived supernatants. In
another setting, freshly isolated splenocytes (2.10
5 cells/well) from
tumor bearing mice were cultured with the syngeneic TIII
melanoma cell line (10
3 cells/well) [34]. Splenocytes were used
either directly or after depletion of CD11b
+ cells.
CFSE labeling and IFNc secretion of TCR transgenic T
cells
CD8 T cells from lymph nodes of OT-1 mice were prepared
using a mouse CD8 negative isolation kit (Dynal Biotec, Oslo,
Table 1. Primer pairs used for real time PCR experiments.
Target cDNA Upper/Lower Sequences (5’ to 3’)
GAPDH U GCC GGT GCT GAG TAT GTC GT
L GGA GAT GAT GAC CCG TTT GG
IL10 U GGT TGC CAA GCC TTA TCG GA
L ACC TGC TCC ACT GCC TTG CT
ARG1 U ATG GAA GAG ACC TTC AGC TAC
L GCT GTC TTC CCA AGA GTT GGG
FIZZ1 U CCC AGG ATG CCA ACT TTG AA
L GGC CCA TCT GTT CAT AGT CT
MGL1 U ATG ATG TCT GCC AGA GAA CC
L ATG ATG TCT GCC AGA GAA CC
EMR1 U CTC ACC GGT ATA GAC AA
L GCA GGC GAG GAA
CCL2 U TTA AAA ACC TGG ATC GGA ACC AA
L GCA TTA GCT TCA GAT TTA CGG GT
doi:10.1371/journal.pone.0020235.t001
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5.10
4 CFSE
+ cells were cultured for 72 h in presence or not of
Ova257 (8.10
24 mM) with 5.10
5 CD11b
+ cells. The supernatants
were analyzed for IFNc by ELISA using IFNc capture biotinylated
mAb, and streptavidin-alkaline phosphatase (BD biosciences).
CFSE dilution was determined by flow cytometry.
Figure 1. Accumulation of CD11b
+Gr1
high myeloid cells in spleen of tumor bearing MT/ret mice. (A) Comparison of the proportion of
hematopoietic cells in spleen of MT/ret and ctrl mice. Myeloid cells are CD11b
+ cells. abT cells are defined as CD4
+ abTCR
high cells and CD8
+ abTCR
high
cells. cdT cells are defined as CD8- cdTCRhigh cells. B cells are defined as CD19
+CD8
- cells and NK cells are NK1.1
+CD4
-CD8
- cells. The pie diagram
summarizes data from spleens of MT/ret (n=29) and Ctrl (n=13) age matched mice. (B) Single cell suspensions derived from spleens of MT/ret or Ctrl
mice were stained for CD45, CD11b and Gr1. Representative CD11b/Gr1 dot plots were generated from gated CD45
+ cells. (C) The histograms
correspond to the absolute numbers of both CD11b
+Gr1
high cell subsets in ctrl spleens (n=13) and in spleens of MT/ret mice displaying either
primary tumors (n=8), facial (face, n=13) or dorsal cutaneous metastasis (back, n=12). (D) Myeloid cells from MT/ret spleen inhibit the spontaneous
response specific for melanoma. The number of IFNc-secreting cells was assessed by an ELISPOT assay using splenocytes from MT/ret mice as
effectors and Melan-ret cells as targets. Ex vivo splenocytes were used either in total or after depletion of CD11b
+ cells. The significance was assessed
using unpaired t test.
doi:10.1371/journal.pone.0020235.g001
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Total RNA was isolated from purified CD11b
+ cells using
RNAlater and RNeasy columns (Qiagen, Courtaboeuf, France).
RNA was reverse transcribed with SuperScript
TM II (Invitrogen)
and oligo-dT18 primers. Quantitative PCR was carried out using
fast SYBR Green Master Mix (Applied Biosystems) and a real time
PCR system (Light Cycler 1.5, Roche Diagnostics, Division
Applied Sciences, Meylan, France) according to standard PCR
conditions. For quantitative calculations, values were normalized
to GAPDH expression. Primer sequences are listed in Table 1.
Tumor cell proliferation assay
The xCELLigence System (Roche Diagnostics) monitors
cellular events in real time without the incorporation of labels.
The System measures electrical impedance across interdigitated
micro-electrodes integrated on the bottom of tissue culture E-
Plates. The impedance measurement provides quantitative
information about the status of the adherent cells, including cell
number, viability, and morphology. Melan-ret melanoma cells
(5.10
3) were seeded into the wells of 96X E-Plates in 100 mlo f
media. Cell adhesion and growth were monitored 48h till their
exponential growth phase. Tumor derived CD11b
+ purified cells
(5.10
4 cells) were added in a volume of 100 ml/well. Co-cultures
were assessed by the system with a measure every 5 min for up to
40 h. Results, expressed as Cellular Index, were normalized (nCI)
with RTCA Software, and expressed as percentage of specific
inhibition = (1-nCI (Melan-ret cells + CD11b
+ cells) /nCi (Melan-
ret cells))6100.
NO assay
Purified CD11b
+ cells (5.10
5) were cultured for 2 days in RPMI,
10% FCS supplemented with LPS and IFNc. NO was measured
using Griess reagents (Promega, Charbonnie `res-les-Bains). Briefly,
50 ml of culture supernatant was incubated for 10 min at room
temperature with 50 ml of Griess reagent A plus 50 mlo f
Griess reagent B. Absorbance at 540 nm was measured using a
microplate reader (Perkin Elmer). Data are mean +/2SD of trip-
licate wells.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 4.0
software (San Diego, CA).
Results
CD11b
+Gr1
high myeloid cells accumulate in the spleen in
the course of natural melanoma progression
The MT/ret model allowed the monitoring of immune cells
within the spleen and the tumor microenvironment during the
course of spontaneous tumor progression. Exophthalmus corre-
sponds to the first clinical sign of uveal primary melanoma
development. Within 3 months after birth, 50% of mice display
cutaneous metastasis that develop first on the face, then in the
posterior part of the body [34]. The proportions of hematopoi-
etic populations within spleens derived from age matched MT/
ret and ctrl mice were not statistically different (Fig. 1A).
However, CD11b
+ cells consist of two main populations
Figure 2. Characterization of hematopoietic cells within the tumor microenvironment of MT/ret mice. (A) Dot plots from a cell
suspension of one representative cutaneous metastasis. Myeloid and lymphoid stainings were performed as defined in Fig 1A. (B) The pie diagram
summarizes the proportion of hematopoietic cells from 47 cutaneous metastasis. (C) Variability of the proportion of tumor infiltrating CD11b
+ cells
from cutaneous metastasis. The frequencies of CD11b
+ cells gated from CD45
+ cells were determined. The graph shows the data for four 3 month old
mice. (D) Correlation between the tumor aggressiveness and the increase of tumor infiltrating CD11b
+ cells. The tumor aggressiveness corresponds
to the ratio between the absolute numbers of tumor associated cells and the number of days since appearance of each nodule. Statistical differences
were assessed using ANOVA test.
doi:10.1371/journal.pone.0020235.g002
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low (monocytic) and
Gr1
high (granulocytic), and the proportions of CD11b
+ subsets in
MT/ret mice differ from those in ctrl mice. More precisely,
CD11b
+Gr1
high cells accumulate in spleen of mice displaying
dorsal metastasis corresponding to a late melanoma stage (Fig. 1B
and C). In addition, we have previously shown that MT/ret mice
Figure 3. Characterization of myeloid cells from MT/ret mice. (A) QPCR. CD11b
+ cells were isolated from tumors and spleens of tumor
bearing MT/ret mice. The transcripts levels of a panel of genes were analyzed by RT-PCR. Mean values+/2 SEM of relative expression are shown for
indicated genes. (B) Phenotype and function of CD11b
+ cells. Cell suspensions from tumors and spleens of MT/ret mice were stained for CD45, CD11b
and IL4-Ra, F4/80 and IL12 and their isotype controls (grey histogram). Representative stainings for spleen (single line) and tumor (bold line) are
shown. IL-12/CD11b
+ dot plots generated from gated CD45
+ cells are obtained after stimulation with IFNc and LPS. Representative histograms of
more than 3 experiments and performed on more than 10 samples are shown. Results are expressed as the percentage of IL-12
+ cells from
CD45
+CD11b
+Gr1
+ cells taking account the two Gr1 subsets within spleens. Statistical differences were assessed using unpaired t test.
doi:10.1371/journal.pone.0020235.g003
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disease progression [34]. To evaluate if this anti-tumor immune
response is negatively influenced by myeloid cells in the spleen,
either total splenocytes or CD11b
+ cell-depleted splenocytes
were stimulated with Melan-ret melanoma cells. The removal of
CD11b
+ cells raises the number of splenocytes responding to
melanoma cells (Fig. 1D). Together our data indicate that, as
shown in models of tumor transplantation, myeloid cells
accumulate within spleen of MT/ret mice and prevent optimal
anti-tumor T cell response.
Accumulation of myeloid cells within cutaneous
metastasis correlates with the tumor aggressiveness
To extent these data to the monitoring of the tumor mic-
roenvironment, we first compared the proportion of hematopoietic
cells that infiltrate cutaneous metastasis derived from 3 to 6 month
old MT/ret mice (Fig. 2A, 2B). CD45
+ cells represent 2.3% of total
cells. abT and B cells represent on an 6+/20.5% and 6.7+/
20.8% of hematopoietic cells respectively. The percentages
of cdT and NK cells are pretty low. More interestingly, the
percentage of CD11b
+ cells ranges from 11.6 to 92.4% with an
average 76.1% of CD45
+ cells and they are almost exclusively
Gr1
low. In a given mouse, the proportion of CD11b
+ cells could be
variable from tumor to tumor as shown in Fig. 2C for 4 mice. In
order to evaluate the association of tumor infiltrating myeloid cells
with tumor progression for one given nodule, we defined a ‘‘tumor
aggressiveness score’’ corresponding to the ratio between the
absolute number of cells in the tumor and the number of days
since its appearance. The most aggressive tumors (.2.10
5 cells/
day) displayed a high proportion of CD11b
+ cells, whereas the less
aggressive ones (,2.10
4 cells/day) are significantly less infiltrated
by myeloid cells (Fig. 2D). Tumors with intermediate aggressive-
ness already displayed an increased proportion of CD11b
+ cells.
Tumor infiltrating myeloid cells express markers of M2
type macrophages
To further compare myeloid cells that accumulate during tumor
progression, quantitative PCR were carried out on CD11b
+
purified cells from spleen and tumor samples using a set of type 2
myeloid-associated marker genes. QPCR analysis revealed that
il10, arginase I, mgl1 fizz1 and the inflammatory chemokine ccl2
mRNA levels were all significantly higher in tumor derived
CD11b
+ cells (Fig. 3A). In addition, these cells were strongly
positive for F4/80 mRNA compared to related cells in spleen.
Flow cytometric analysis further showed that tumor infiltrating
myeloid cells express F4/80 at the protein level, revealing a
significant upregulation of this macrophage marker in the tumor
microenvironment (Fig. 3B). In addition, tumor infiltrating
myeloid cells express IL-4Ra (Fig. 3B). Contrasting with tran-
splanted tumor models [12], IL-4Ra expression in spleen of
tumor-bearing MT/ret mice is low (Fig. 3B) and similar to the
level observed in splenocytes from control mice (data not shown).
A relatively low proportion of tumor infiltrating myeloid cells
secrete IL-12 upon a short IFNc/LPS stimulation (2.7+/20.8;
Fig. 3B), a proportion quite similar to that of related splenic
myeloid cells. Overall, tumor infiltrating myeloid cells are enriched
in F4/80
+, IL-4Ra
+ cells and only a minority of them have the
capacity to produce IL-12.
Tumor and spleen derived myeloid cells impairs T cell
functions
To compare the impact of myeloid cells from tumor bearing
MT/ret mice on T cell functions, we first stimulated T cells from
GP33 immunized mice with GP33 in the presence of CD11b
+
cells. CD11b
+ cells isolated from tumors or spleens of MT/ret
mice inhibit IFNc secretion (78% and 61% inhibition respectively)
(Fig. 4A, upper histogram). Supernatants from tumor- or spleen-
derived CD11b
+ cells of MT/ret mice also reduced the
proportions of IFNc secreting T cells (49% and 40% inhibition
respectively), while supernatant from control mice had no effect
(Fig. 4A, lower histogram). In addition, we cultured CD11b
+ cells
with CD8
+ T cells specific for Ova257 peptide from OT-1 mice.
In the presence of Ova257 and control CD11b
+ cells, a majority of
OT-1 cells undergoes three to four cycles, whereas CD11b
+ cells
derived from tumors or spleens of MT/ret mice reduced Ova257
specific T cell division (Fig. 4B). Together our data indicate that
despite their phenotypic differences described above, both splenic
and tumor derived myeloid populations inhibit CD8
+ T cell
proliferation and IFNc secretion.
Figure 4. CD11b
+ cells from MT/ret mice suppress T cell
functions. (A) GP33-specific T cells from GP33-immunized mice were
stimulated 24 h with GP33 in presence of CD11b
+ cells isolated either
from tumors or spleens of MT/ret mice or ctrl spleens. The frequency of
IFNc secreting T cells was determined by an ELISPOT assay. The
percentage of inhibition indicated on the graph corresponds to the
ratio between the number of spots in presence and in absence of
CD11b
+ (upper histogram). GP33-specific T cells were also stimulated
with GP33 together with supernatants of CD11b
+ cells isolated from
tumors or spleens of MT/ret or non transgenic mice and tested as above
(lower histogram). (B) Purified OT-1 CD8
+ T cells labeled with CFSE were
cultured in presence of CD11b
+ cells isolated from spleens or tumor
nodules from MT/ret mice or from ctrl spleen, and stimulated in
presence or not of Ova257. Three days later, proliferation was
determined. CFSE fluorescences are shown after culture with (bold
lines) or without Ova257 (thin lines).
doi:10.1371/journal.pone.0020235.g004
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tumor infiltrating myeloid cells
To investigate the impact of T cells on the composition of
hematopoietic cells within the tumor microenvironment and in
particular on tumor infiltrating myeloid cells, we crossed MT/ret
mice with CD3eKO mice. We found no change in the proportion
of hematopoietic cells in mice competent (RetCD3e
+) and deficient
(RetCD3eKO) for T cells. Tumor infiltrating myeloid cells
represent 79% and 81% of CD45
+ cells (Fig. 5A) and express a
similar level of IL-4Ra (Fig. 5B) in the presence or in absence of T
cells respectively. Interestingly, myeloid cells derived from
RetCD3eKO mouse tumors exhibit a better capacity to
secreteIL-12 (Fig. 5B) and NO (Fig. 5C) than the related cells
from age-matched RetCD3e
+ mice. Moreover, they display a poor
inhibitory effect on GP33-specific T cells stimulated with GP33
compared to myeloid cells from tumors of mice competent for T
cells (Fig. 5D). By contrast, the proportion of IL-12 producing
CD11b
+ cells in spleen and their capacity to impair T cell
functions are similar in both groups of animals lpar;not shown).
T cells favor pro-tumoral properties of tumor infiltrating
myeloid cells
The proliferation of Melan-ret cells was dynamically moni-
tored in vitro in presence of tumor derived CD11b
+ cells from
RetCD3eKO or RetCD3e
+ mice. These latter were added at 48 h
when tumor cells reached their exponential growth phase (Fig 6A).
According to their M2 phenotype, intratumoral myeloid cells from
T cell competent mice promote tumor cell proliferation as shown
by the cell index increase, whereas no significant cell index is
recorded in wells with CD11b
+ cells alone (Fig. 6A). Conversely,
myeloid cells from RetCD3eKO mice inhibited Melan-ret cell
proliferation within few hours. Indeed, in 7 cases out of 10,
CD11b
+ cells from RetCD3eKO mice inhibited from 5 to 98% of
the proliferation, whereas related CD11b
+ cells from RetCD3e
+
mice do it in only 1 case out of 8 (Fig 6B). After 40 hours, the
tumor cell proliferation tested in three independent experiments is
statistically different between the two groups (Fig 6C). Thus, our
data suggest that T cells do not interfere with the recruitment of
myeloid cells within the tumor microenvironment, but improve
their suppressive and pro-tumoral functions. To assess whether
such a different myeloid cell properties correlated with reduced
melanoma progression, we diagnosed carefully melanoma symp-
toms in mice competent and deficient for T cells. Mice from both
groups develop primary melanoma with a similar kinetic (Fig. 7A).
No significant difference was also observed in the onset of
cutaneous metastasis (Fig. 7B). Interestingly, at 6 month of age, the
absolute number of tumor cells within metastasis per mouse is
significantly lower in RetCD3eKO mice than in T cell competent
Figure 5. T cells contribute to the immunosuppressive function of tumor infiltrating myeloid cells. (A) The graphs indicate the
proportion of CD45
+ cells from live cells and myeloid cells from CD45
+ cells from tumors of RetCD3e
+ (n=15) and RetCD3eKO (n=16) age matched
mice. (B) Cell suspensions from tumors derived from RetCD3e
+ and RetCD3eKO mice were stained for CD45, CD11b and IL4-Ra. Representative
histograms are shown for IL4-Ra expression from CD45
+CD11b
+ cells. The histograms below summarize the MFI ratio of IL4-Ra specific staining on
the isotype staining. Cell suspensions were also stained for CD45, CD11b and IL-12 after LPS and IFNc stimulation. Representative IL-12/CD11b dot
plots generated from gated CD45
+ cells are shown. The histograms below summarize the proportion of IL-12 secreting cells from tumor infiltrating
CD11b
+ cells. Purified tumor infiltrating CD11b
+ cells were activated with LPS and IFNc for two days and assessed for NO production (C). (D) GP33-
specific T cells (as in Figure 4.A) were stimulated 24 h with GP33 in presence of CD11b
+ cells isolated from tumors of RetCD3e
+ (n=5) or RetCD3eKO
(n=5) mice. T cell inhibition by myeloid cells is determined by comparing the frequency of IFNc secreting cells in absence and in presence of CD11b
+
cells.
doi:10.1371/journal.pone.0020235.g005
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of E-plates. After 48 h, at the time tumor cells were in exponential growth phase (arrow), tumor infiltrating CD11b
+ cells isolated either from RetCD3e
+
and RetCD3eKO mice were added and the tumor cell proliferation was assessed by dynamically monitored every 15 min on cell impedance. The
graph shows the nCI values obtained by the RT-CES system for two representative CD11b
+ cells isolated from mice deficient or competent for T cells.
(B) The percent of inhibition of Melan-ret cell proliferation was calculated as described in Materials and Methods, 40 hours after addition of myeloid
cells. (C) The statistical significance between the effect of CD11b
+ cells from RetCD3e
+ (n=8) and RetCD3eKO (n=10) mice tested within three
independent experiments was assessed using unpaired t test.
doi:10.1371/journal.pone.0020235.g006
Figure 7. Cutaneous metastasis are smaller in T cell deficient mice than in T cell competent mice. The onset of the primary tumor (A) and
of cutaneous metastasis (B) is shown for RetCD3e
+ (n=16) and RetCD3eKO (n=11) mice. (C) The mean absolute number of tumor cells within
cutaneous metastasis per mouse is determined after enzyme digestion for more than 5 mice per group.
doi:10.1371/journal.pone.0020235.g007
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the absence of T cells.
Discussion
It has been well established that myeloid cells accumulate in the
spleen during tumor progression and inhibit the anti-tumor T cell
response [12]. Movahedi et al identified Ly6G
- mononuclear and
Ly6G
+ polymorphonuclear myeloid cells in the spleen of tumor-
bearing mice [3]. In MT/ret mice, splenic CD11b
+ cells with a
low or high Gr1 expression may correspond to the former and the
latter fractions respectively. In the spleen of MT/ret mice, the
CD11b
+Gr1
high myeloid subset tends to accumulate as tumors
progress, but the expansion becomes significant only at the latest
stage of the disease. By contrast, myeloid cells always dominate the
tumor infiltrate and the proportion of tumor infiltrating CD11b
+
cells is associated with clinical aggressiveness. Accordingly, Soudja
et al have recently shown that CD11b
+ cells were more frequent in
more aggressive melanomas in the induced melanoma model of
TiRP mice [36].
We show that, during spontaneous tumor progression, M2 type
marker genes (e.g. arginase1, il10, mgl1, fizz1,) are significantly
upregulated in tumor infiltrating CD11b
+ cells compared to
related splenic cells. The low level of IL-4Ra on splenic myeloid
cells from MT/ret mice, similar to that in negative littermates, is
consistent with data in transplanted tumor models indicating that
the suppressive function of splenic MDSC does not always involve
a high expression of this marker [12,37]. Arginase production by
myeloid cells requires IL4 and IL13 signaling [38]. In MT/ret
mice, IL-4Ra is significantly more expressed on tumor infiltrating
CD11b
+ cells than on their splenic counterparts. Accordingly,
myeloid cells produce more arginase at the tumor site than in the
spleen. Finally, all tumor infiltrating myeloid cells express high
levels of F4/80 which clearly contrast with splenic myeloid cells
that weakly express this marker. Thus, tumor microenvironment
contains mononuclear cells that have differentiated into macro-
phages. It has been proposed that classical M1 macrophages
infiltrate the site of chronic inflammation where tumors initially
develop, while tumor-promoting M2 like macrophages expressing
low levels of inflammatory cytokines such as IL-12 progressively
replace them in established tumors [39]. Consistent with this
model, the proportion of TAM able to produce IL-12 decreases in
MT/ret mice with melanoma progression (not shown). Finally,
spleen and tumor derived myeloid cells from MT/ret mice inhibit
efficiently antigen specific T cell proliferation and IFNc secretion.
Splenic myeloid cells also impair the anti-tumor reactivity of
autologous splenocytes indicating that these cells correspond to
tumor-induced MDSC. Thus, tumor growth in the MT/ret
model induces the replacement of normal splenic myeloid cells by
suppressive cells and the recruitment of immunosuppressive mye-
loid cells at the tumor site.
While the role of innate immune cells in polarizing the adaptative
immune response is well established [40], little is known on the
reciprocal involvement of T cells in promoting the expansion
and/or suppressive activity of myeloid cells [14,31]. In a murine
HPV16-induced epithelial cancer and more recently in a model of
transplanted ovarian cancer, CD4
+ T cells have been shown to
promote the recruitmentofmyeloid cellsintotumors[41,42].Inour
model, the proportion of tumor infiltrating myefloid cells is
comparable in RetCD3eKO and RetCD3e
+ mice, indicating
that their recruitment does not require T lymphocytes. Tumor
infiltrating lymphocytes may rather condition intra-tumoral
myeloid cells towards a M2 type macrophage profile, as suggested
bydata obtainedinnude miceinoculatedwithtumorcells[43].Our
data show that tumor infiltrating myeloid cells from RetCD3eKO
mice display a better capacity to secrete IL-12 and produce more
NO than related cells in RetCD3e
+ mice. They only poorly impair
the capacity of T cells to secrete IFNc in response to antigen specific
stimulation. Finally, they inhibit Melan-ret cell proliferation within
few hours in contrast to intra-tumoral myeloid cells from T cell
competent mice, revealing their higher cytotoxic activity towards
tumor cells. Together, our data suggest that T cells affect myeloid
differentiation within the tumor microenvironment and regulate
their immunosuppressive and pro-tumoral properties. These data
are in agreement with recent data in a model of breast cancer
showing for the first time that IL4 producing CD4
+ T cells promote
pro-tumoralpropertiesofTAMbyreducingtheirexpression levelof
type 1 cytokines [44].
Many reports, including ours in the MT/ret model [33,45],
support the idea that T cells exert a protective role against
dissemination of metastatic cells. The present data show in
addition that the genetic elimination of T cells does not accelerate
the primary melanoma onset. Cutaneous metastasis develop with a
similar kinetic in both RetCD3eKO and RetCD3e
+ mice. More
surprisingly, cutaneous metastasis were smaller in T cell deficient
mice than in RetCD3e
+ mice, suggesting a pro-tumor activity of T
cells. Accordingly, DeNardo et al have recently revealed a
significant role of CD4
+ T cells as potentiators of pulmonary
metastasis of mammary carcinomas through their influence on
pro-tumor properties of TAM [44]. In our model, we do not
privilege a pro-tumoral role of CD8 T cells, as they interfere with
visceral metastasis spreading at early [33] and late [45] stages of
melanoma development. Further experiments will be needed to
identify which T cell subset (e.g. conventional CD4 T cells,
regulatory T cells or NKT cells) was regulating intra-tumoral
myeloid cell functions and what kind of mechanism is involved
(e.g. IL4, IL10, IL13 or IL17) in this process in the course of
melanoma progression. The unexpected clinical impact of T cell
deficiency in MT/ret mice may be in part due to a direct
regulation of the cytotoxic activity of myeloid cells towards tumor
cells as suggested by our dynamic melanoma cell index
monitoring. We cannot exclude that they also impact angiogenesis
and extracellular matrix remodeling. Alternatively, the higher
proportion of intra-tumoral myeloid cells able to secrete IL12 may
also improve tumoricidal NK cell activity [46].
Altogether, our present data suggest that T cells establish an
environment that is likely to skew tumor infiltrating myeloid cells
toward a tumor promoting response. They support the existence of
an immunosuppressive vicious circle in which T cells favor
melanoma development by inducing a switch towards a
suppressive profile of myeloid cells that, in turn, suppress T cell
functions.
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